Literature DB >> 2564971

Ursodeoxycholic acid in primary biliary cirrhosis.

M C Bateson, P E Ross, B L Diffey.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2564971     DOI： 10.1016/s0140-6736(89)92888-2

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  7 in total

1.  Ursodeoxycholic acid therapy in chronic active hepatitis.

Authors:  M C Bateson
Journal:  Postgrad Med J       Date:  1990-09       Impact factor: 2.401

2.  New directions in primary biliary cirrhosis.

Authors:  M C Bateson
Journal:  BMJ       Date:  1990-12-08

3.  Effect of intraduodenal administration of 23-methyl-UDCA diastereoisomers on bile flow in hamsters.

Authors:  C Clerici; G Dozzini; E Distrutti; G Gentili; B M Sadeghpour; B Natalini; R Pellicciari; R Rizzoli; A Roda; M A Pelli
Journal:  Dig Dis Sci       Date:  1992-05       Impact factor: 3.199

4.  Effects of ursodeoxycholic acid (UDCA) on serum liver damage indices in patients with chronic active hepatitis. A double-blind controlled study.

Authors:  E Rolandi; R Franceschini; A Cataldi; V Cicchetti; L Carati; T Barreca
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

Review 5.  Ursodeoxycholic acid in chronic liver disease.

Authors:  J S de Caestecker; R P Jazrawi; M L Petroni; T C Northfield
Journal:  Gut       Date:  1991-09       Impact factor: 23.059

6.  Different protective effects of tauroursodeoxycholate, ursodeoxycholate, and 23-methyl-ursodeoxycholate against taurolithocholate-induced cholestasis.

Authors:  U Baumgartner; J Schölmerich; M Sellinger; M Reinhardt; G Ruf; E H Farthmann
Journal:  Dig Dis Sci       Date:  1996-02       Impact factor: 3.199

7.  A dose-up of ursodeoxycholic acid decreases transaminases in hepatitis C patients.

Authors:  Shuichi Sato; Tatsuya Miyake; Hiroshi Tobita; Naoki Oshima; Junichi Ishine; Takuya Hanaoka; Yuji Amano; Yoshikazu Kinoshita
Journal:  World J Gastroenterol       Date:  2009-06-14       Impact factor: 5.742
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.